The initial wave of Generative AI excitement in the life sciences is meeting a sobering reality: the “Implementation Gauntlet.” While the potential for AI to revolutionize the DMTA cycle is undisputed, many organizations remain trapped in “Pilot Purgatory,” unable to scale individual successes into enterprise-wide impact. Our latest whitepaper, “From Hype to Implementation,” deconstructs this […]
From Hype To Implementation Read More »
Over the past year, we’ve seen a sea change in drug discovery — from the adoption of AI & advanced automation to changes in the funding landscape and talent space. In our State of Play: 2025 report, we lay it all out for you.
BioPharma State of Play: 2025 Read More »
One of the aspects of drug discovery project management that generates a certain amount of consternation is the underlying difference in the nature of a drug discovery project versus a drug development program – the Great Divide that I wrote about previously. In the beginning, virtually everything that can impact the timeline of a drug
Across The Great Divide: Part 2 Read More »
One of the things I enjoy most about the Why Summits conferences is the opportunity to talk with people from across the drug discovery spectrum and learn about both their challenges and how they dealt with them. There has always been a Great Divide between the discovery and development arms of drug discovery organisations, driven
Across The Great Divide: Part 1 Read More »
As a boy growing up in a village on the outskirts of Vienna, this time of year always held a certain amount of excitement and trepidation for me. Every year on the evening of December 5th, after a feverish amount of shoe polishing, and sweeping of the front porch we would await the arrival of
Beyond JPM 2025: Streamlining Biotech Project & Portfolio Management Read More »
2024 has been a year of exciting advancements at Aspen Biosciences, marked by the expansion of our Pipeline and PharmExchange platforms and the launch of innovative features designed to empower drug discovery efforts and to improve their capital efficiency. We’re thrilled to share some of the highlights: New Modules: New Features: Overall, these new modules
2024: Year In Review Read More »
Lessons Learned Creating a new drug discovery software platform is a complex process. We’ve spent the last 15 years creating new and innovative tools for drug discovery companies – everything from custom reagent management systems, to kinase profiling tools, automated chemistry, protein production and DEL-based drug discovery platforms. In addition to managing the day-to-day aspects
One of the key lessons learned from all of the implementations that we’ve done is a need for flexibility. A customer might tell us that they need X, but it often evolves into Y over the course of the project. Creating a system that is evolvable has its own unique challenges: Over the years
Metadata-Driven Collaboration in Biotech and Pharma: Pipeline – Origins Stories, Pt 2 Read More »
When I started Aspen Biosciences in 2009, I had one thing in mind — to make the process of drug discovery easier and more manageable for the people doing it. Having spent time at both mid-size biotech companies like Lexicon Pharmaceuticals and at large pharmaceutical companies like Pfizer and Takeda I had seen first-hand a
Pipeline: Origin Stories, Pt 1 Read More »
Today is International Women’s Day. Please join me in celebrating some of the women who have made significant contributions to our understanding of pancreatic cancer through PanCAN Research Grants.
International Women’s Day Read More »
